07:00 , May 13, 2013 |  BC Week In Review  |  Company News

BioHelix, Quidel deal

Quidel acquired BioHelix for $10 million in cash, plus R&D and commercial milestones based on the completion of a designated number of assays and product sales over a defined period. The companies partnered in 2009...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

IsoAmp HSV Assay regulatory update

FDA granted 510(k) clearance for BioHelix's IsoAmp HSV Assay as an aid in diagnosing herpes simplex virus (HSV). The in vitro diagnostic, which is based on the company's Helicase-Dependent Amplification (HDA) technology, qualitatively detects HSV...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Company News

BioHelix, Quidel deal

BioHelix will use its isothermal amplification technology to develop assays for in vitro molecular diagnostics for infectious pathogens. Quidel will fund assay development and have exclusive, worldwide rights to manufacture and commercialize any assays developed...
07:00 , May 5, 2008 |  BC Week In Review  |  Company News

BioHelix Corp., Qiagen deal

Qiagen received a worldwide, non-exclusive license to use BioHelix's Helicase Dependent Amplification (HDA) assay technology. HDA is used to detect and analyze biological target molecules such as DNA and RNA by amplifying target-specific genetic information....